PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Finan, B.* ; Douros, J.D.* ; Goldwater, R.* ; Hansen, A.M.K.* ; Hjerpsted, J.B.* ; Hjøllund, K.R.* ; Kankam, M.K.* ; Knerr, P.J.* ; Konkar, A.* ; Mowery, S.A.* ; Müller, T.D. ; Nielsen, J.R.* ; Nygård, S.B.* ; Perez-Tilve, D.* ; Raun, K.* ; Yang, B.* ; Tschöp, M.H. ; DiMarchi, R.D.*

A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans.

Mol. Metab. 96:102129 (2025)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Single molecules that combine complementary modes of action with glucagon-like peptide-1 receptor (GLP-1R) agonism are best-in-class therapeutics for obesity treatment. NN1706 (MAR423, RO6883746) is a fatty-acylated tri-agonist designed for balanced activity at GLP-1R and glucose-dependent insulinotropic polypeptide receptor (GIPR) with lower relative potency at the glucagon receptor (GcgR). Obese mice, rats and non-human primates dosed with NN1706 showed significant body weight reductions and improved glycemic control. In human participants with overweight or obesity, daily subcutaneous NN1706 treatment resulted in substantial body weight loss in a dose-dependent manner without impairing glycemic control (NCT03095807, NCT03661879). However, increased heart rate was observed across NN1706 treatment cohorts, which challenges further clinical development of NN1706.
Impact Factor
Scopus SNIP
Altmetric
6.600
0.000
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Clinical ; Glucagon ; Incretins ; Obesity; Glycemic Control; Double-blind; Phase 1b; Agonist; Glucagon; Glp-1; Pharmacokinetics; Liraglutide; People; Gip
Language english
Publication Year 2025
HGF-reported in Year 2025
ISSN (print) / ISBN 2212-8778
e-ISSN 2212-8778
Journal Molecular Metabolism
Quellenangaben Volume: 96, Issue: , Pages: , Article Number: 102129 Supplement: ,
Publisher Elsevier
Publishing Place Amsterdam
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Obesity (IDO)
POF-Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-501900-221
G-502200-001
Grants Novo Nordisk A/S
DOI 10.1016/j.molmet.2025.102129
WOS ID 001480624600001
Scopus ID 105003257780
PubMed ID 40139439
Erfassungsdatum 2025-05-09
[➜Report correction]